This article was originally published in Start Up
Axonyx is offering a portfolio of second-generation Alzheimer's therapeutics.
You may also be interested in...
We're still in the iron lung age of Alzheimer's treatment. When the new Jonas Salk comes along, ideas will change dramatically.
Oxagen's goal is to use large familial clinical groups and sample banks to identify disease genes through agreements with three groups of academic clinical investigators, located throughout Europe.
PolyGenomics was spun-out of Yale University to develop a genetic amplification technology in the search for genes implicated in psychiatric illnesses.